Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Chris, Feierabend"'
Autor:
Kimberly Binger, Jennifer Volkman, Sandra Black, Sherry Morgan-Meadows, Dona Alberti, George Wilding, Marcia Pomplun, Shawna Ellingen, Howard H. Bailey, Rhoda Arzoomanin, Rebecca Marnocha, Sarita Dubey, Kendra D. Tutsch, Chris Feierabend, Michael N. Gould
Publikováno v:
Cancer Chemotherapy and Pharmacology. 52:361-366
Previous experience with perillyl alcohol (POH) was with a formulation of 500-mg capsules each containing 250 mg POH and soybean oil. This formulation resulted in the ingestion of large amounts of soybean oil (>10 g/day). Dose-limiting toxicities (DL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::113282b104330dc4dd69c9042332d275
https://doi.org/10.1007/s00280-003-0684-y
https://doi.org/10.1007/s00280-003-0684-y
Autor:
Jennifer Volkman, Rebecca Marnocha, Chris Feierabend, Dona Alberti, Rhoda Z. Arzoomanian, Kimberly Binger, Howard H. Bailey, George Wilding, James P. Thomas, Glenn Liu
Publikováno v:
American Journal of Clinical Oncology. 26:280-284
Piritrexim is a new antifolate that has shown activity in methotrexate-resistant tumors. Gemcitabine is an antimetabolite similar in structure to cytosine arabinoside with early studies demonstrating activity in a variety of cancers. It also has appa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96fedb2228817666bff8177426e118d
https://doi.org/10.1097/01.coc.0000081607.16287.6f
https://doi.org/10.1097/01.coc.0000081607.16287.6f
Autor:
Kimberly Binger, Kris Simon, Howard H. Bailey, Amy Dresen, Chris Feierabend, Kendra D. Tutsch, Rhoda Z. Arzoomanian, James F. Cleary, Rebecca Marnocha, James P. Thomas, Dona Alberti, George Wilding
Publikováno v:
Cancer Chemotherapy and Pharmacology. 50:465-472
Purpose. Flavopiridol (NSC 649890) is a synthetic flavone possessing significant antitumor activity in preclinical models. Flavopiridol is capable of inducing cell cycle arrest and apoptosis, presumably through its potent, specific inhibition of cycl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e2c527595d187521eb1bd3a22c0e88e
https://doi.org/10.1007/s00280-002-0527-2
https://doi.org/10.1007/s00280-002-0527-2
Phase I Study of Eniluracil, Oral 5-Fluororacil and Gemcitabine in Patients with Advanced Malignancy
Autor:
Rhoda Z. Arzoomanian, George Wilding, Howard H. Bailey, Jordan Berlin, Kim Binger, James P. Thomas, Jennifer Volkman, Daniel Mulkerin, Sherry Morgan-Meadows, Dona Alberti, Chris Feierabend, Rebecca Marrocha
Publikováno v:
Investigational New Drugs. 20:377-382
The objectives of this trial were to assess the maximal tolerated dose and toxicity of the combination of oral eniluracil and 5-fluorouracil and intravenous gemcitabine.Patients with histologically confirmed, incurable malignancy (solid tumor or lymp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df013918856ebcaad72951d1e5b2067d
https://doi.org/10.1023/a:1020673928704
https://doi.org/10.1023/a:1020673928704
Autor:
Kris Simon, Dona Alberti, Rhoda Z. Arzoomanian, Rebecca Marnocha, Jordan Berlin, Chris Feierabend, Kim Binger, George Wilding
Publikováno v:
Investigational New Drugs. 16:325-330
Introduction: This was a dose escalation phase I trial designed to establish the MTD (maximum tolerated dose) and toxicity profile of the combination of gemcitabine, leucovorin and 5-fluorouracil (5-FU). Methods: Standard eligibility criteria were re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::310bf98588b508df40e63d565900ef7b
https://doi.org/10.1023/a:1006242005837
https://doi.org/10.1023/a:1006242005837
Autor:
Barry E. Storer, Chris Feierabend, Rhoda Z. Arzoomanian, Joan H. Schiller, David R. Spriggs, Dona Alberti, Kendra D. Tutsch
Publikováno v:
Journal of Clinical Oncology. 12:241-248
PURPOSE We conducted a phase I trial of a 3-hour infusion of Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) to identify the maximum-tolerated dose of Taxol as a 3-hour infusion with and without granulocyte colony-stimulating factor (G-CSF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::561af9ea2ab295c704379d50fd757edc
https://doi.org/10.1200/jco.1994.12.2.241
https://doi.org/10.1200/jco.1994.12.2.241
Autor:
Jennifer Volkman, Joan H. Schiller, Sarita Dubey, George Wilding, Kim Binger, Rhoda Z. Arzoomanian, Paul R. Hutson, Dona Alberti, Chris Feierabend
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 11(4)
Background. Docetaxel and topotecan are drugs with different mechanisms of action and significant activity against various tumour types. Topotecan may influence docetaxel metabolism by inhibiting the CYP3A4 enzyme. We designed a phase I study to eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4657c7d22ac13e2a3c11a539f7d20a4c
https://pubmed.ncbi.nlm.nih.gov/16595064
https://pubmed.ncbi.nlm.nih.gov/16595064
Autor:
Chris Feierabend, David M. King, Dona Alberti, Marcia Pomplun, Rhoda Z. Arzoomanian, Kendra D. Tutsch, George Wilding
Publikováno v:
Investigational new drugs. 22(2)
Background: This phase I study was conducted to determine maximal tolerated dose (MTD) and dose-limiting toxicities (DLT) in patients with advanced solid tumors treated with the polyamine analog N1,N14-diethylhomospermine (DEHSPM). Methods: Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e17bfb0b956e33f76e782f5cbc27073
https://pubmed.ncbi.nlm.nih.gov/14739661
https://pubmed.ncbi.nlm.nih.gov/14739661
Autor:
Kriste A. Lewis, Rhoda Z. Arzoomanian, Jan Stewart, Howard H. Bailey, Sarah A. Holstein, Kendra D. Tutsch, George Wilding, Raymond J. Hohl, Chris Feierabend, Dona Alberti, Kris Simon, Rebecca Marnocha
Publikováno v:
Cancer chemotherapy and pharmacology. 54(4)
Perillyl alcohol (POH) has been shown to have both chemopreventative and chemotherapeutic activities in preclinical studies. The underlying mechanism(s) of action of POH have yet to be delineated but may involve effects on the transforming growth fac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fdb9acd36e495f33de5131a1f61fb3e
https://pubmed.ncbi.nlm.nih.gov/15205914
https://pubmed.ncbi.nlm.nih.gov/15205914
Autor:
Joseph, Merchant, Kendra, Tutsch, Amy, Dresen, Rhoda, Arzoomanian, Dona, Alberti, Chris, Feierabend, Kim, Binger, Rebecca, Marnoccha, James, Thomas, Jim, Cleary, George, Wilding
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 8(7)
NSC 655649 was given in both single- and multiple-dose formats, to characterize maximum tolerated dose (MTD), toxicity, and pharmacokinetic profile.Patients with advanced malignancies were treated with escalating doses of NSC 655649 in either a singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a17e37a66201a1e587ce27b1db42530a
https://pubmed.ncbi.nlm.nih.gov/12114420
https://pubmed.ncbi.nlm.nih.gov/12114420